National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group (BCB-Sarcomes)

August 28, 2025 updated by: Institut Bergonié

The "BCB-sarcomes" Database: the Database of the French Sarcoma Group Dedicated to the Collection of Clinical and Biological Data for All Sarcomas

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas [RESOS] / French expert network dedicated to the pathology of sarcomas [RREPS]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas [NETSARC]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.

Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.

With the financial support of the French National Cancer Institute [Institut National du cancer [INCa]).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

150000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Bordeaux, France
        • Recruiting
        • Institut Bergonié, Comprehensive Cancer Center
        • Contact:
          • Maud Toulmonde, MD
        • Contact:
          • Antoine Italiano, MD/PhD
      • Lyon, France
        • Recruiting
        • Centre Leon Berard
        • Contact:
          • Jean-Yves Blay, MD/PhD
      • Villejuif, France
        • Recruiting
        • Institut Gustave Roussy, Comprehensive Cancer Center
        • Contact:
          • Axel Le Cesne, MD/PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Diagnosis of sarcoma

Description

Inclusion criteria :

  • Diagnosis of sarcoma
  • Diagnosis in a French Comprehensive Cancer Center
  • Any age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with sarcoma
Patients with a sarcoma diagnosed in a French Comprehensive cancer Center
Drug: Chemotherapy
treatment as per standard of care
Drug: Immunotherapeutic Agent
treatment as per standard of care
Drug: target treatment
treatment as per standard of care
Procedure: Surgery
treatment as per standard of care
Radiation: Radiotherapy
treatment as per standard of care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to next treatment (TNT)
Time Frame: 2 years
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
2 years
Time to next treatment (TNT)
Time Frame: 5 years
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
5 years
Overall survival (OS)
Time Frame: 2 years
Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.
2 years
Overall survival (OS)
Time Frame: 5 years
Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Bergonié

Collaborators

French Sarcoma Group

Investigators

  • Study Chair: Maud Toulmonde, MD, Institut Bergonié, Bordeaux, France
  • Study Chair: Axel Le Cesne, MD/PhD, Institut Gustave Roussy, Villejuif, FRANCE
  • Study Chair: Jean-Yves Blay, MD/PhD, Centre Léon Bérard, Lyon, France

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2010

Primary Completion (Estimated)

December 31, 2030

Study Completion (Estimated)

December 31, 2035

Study Registration Dates

First Submitted

June 5, 2019

First Submitted That Met QC Criteria

June 5, 2019

First Posted (Actual)

June 6, 2019

Study Record Updates

Last Update Posted (Estimated)

September 4, 2025

Last Update Submitted That Met QC Criteria

August 28, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IB2012-BCB-SARCOMES

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcoma

Clinical Trials on Chemotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe